Drug Profile
CNTX 6970
Alternative Names: CNTX-6970Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Anti-inflammatories; Non-opioid analgesics; Small molecules
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Inflammatory pain
Most Recent Events
- 07 Dec 2022 Phase II development in Inflammatory pain is ongoing in USA (PO) (Centrexion Therapeutics pipeline, December 2022)
- 25 Oct 2021 Massachusetts General Hospital initiates a phase II trial for Inflammatory pain (PO) in USA (NCT05025787)
- 29 Oct 2020 Phase-II clinical trials in Inflammatory pain (due to osteoarthritis) in USA (PO)